{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:22:38Z","timestamp":1793740958856,"version":"4.6.1"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41571-026-01147-w","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:03:23Z","timestamp":1776240203000},"page":"520-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-515X","authenticated-orcid":false,"given":"Alaa","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1847-5165","authenticated-orcid":false,"given":"Metin","family":"Ozdemirli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"1147_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1147_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1432799","volume":"15","author":"A Ali","year":"2024","unstructured":"Ali, A. & DiPersio, J. F. ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights. Front. Immunol. 15, 1432799 (2024).","journal-title":"Front. Immunol."},{"key":"1147_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Current understanding and management of CAR T cell-associated toxicities. Nat. Rev. Clin. Oncol. 21, 501\u2013521 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1147_CR4","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","volume":"31","author":"K Rejeski","year":"2025","unstructured":"Rejeski, K., Hill, J. A., Dahiya, S. & Jain, M. D. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat. Med. 31, 2132\u20132146 (2025).","journal-title":"Nat. Med."},{"key":"1147_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"1147_CR6","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","volume":"3","author":"NN Shah","year":"2019","unstructured":"Shah, N. N. et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 3, 2317\u20132322 (2019).","journal-title":"Blood Adv."},{"key":"1147_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ymthe.2022.12.004","volume":"31","author":"BJ Sasu","year":"2023","unstructured":"Sasu, B. J. et al. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. Mol. Ther. 31, 676\u2013685 (2023).","journal-title":"Mol. Ther."},{"key":"1147_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1172\/JCI130144","volume":"130","author":"CL Nobles","year":"2020","unstructured":"Nobles, C. L. et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J. Clin. Invest. 130, 673\u2013685 (2020).","journal-title":"J. Clin. Invest."},{"key":"1147_CR9","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","volume":"390","author":"M Ozdemirli","year":"2024","unstructured":"Ozdemirli, M. et al. Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy. N. Engl. J. Med. 390, 2074\u20132082 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica, K. et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N. Engl. J. Med. 392, 577\u2013583 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR11","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1182\/blood.2025031423","volume":"147","author":"H Hosoya","year":"2025","unstructured":"Hosoya, H. et al. Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine. Blood 147, 1191\u20131198 (2025).","journal-title":"Blood"},{"key":"1147_CR12","doi-asserted-by":"publisher","first-page":"6033","DOI":"10.1016\/j.ymthe.2025.08.043","volume":"33","author":"E Bezerra","year":"2025","unstructured":"Bezerra, E. et al. Isolated oral CD30+\/CD4+ CAR+ T cell lymphoma in long-term remission after radiotherapy. Mol. Ther. 33, 6033\u20136040 (2025).","journal-title":"Mol. Ther."},{"key":"1147_CR13","doi-asserted-by":"publisher","first-page":"S1081","DOI":"10.14309\/01.ajg.0001147712.54663.2c","volume":"120","author":"LM Zuniga","year":"2025","unstructured":"Zuniga, L. M. et al. Diarrheal dilemma: a case of post-CAR-T T-cell lymphoma presenting as refractory diarrhea. Am. J. Gastroenterol. 120, S1081\u2013S1081 (2025).","journal-title":"Am. J. Gastroenterol."},{"key":"1147_CR14","first-page":"S1305","volume":"120","author":"S Rolak","year":"2025","unstructured":"Rolak, S., Patel, C., Cheng, J., Eller, V. & Umar, S. Persistent diarrhea following CAR-T therapy for multiple myeloma: a case of immune effector cell-associated enterocolitis.Am. J. Gastroenterol. 120, S1305\u2013S1305 (2025).","journal-title":"Am. J. Gastroenterol."},{"key":"1147_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMc2504588","volume":"393","author":"A Aleman","year":"2025","unstructured":"Aleman, A. et al. Targeted therapy of CAR+ T-cell lymphoma after anti-BCMA CAR T-cell therapy. N. Engl. J. Med. 393, 823\u2013825 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","volume":"31","author":"T Braun","year":"2025","unstructured":"Braun, T. et al. Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nat. Med. 31, 1145\u20131153 (2025).","journal-title":"Nat. Med."},{"key":"1147_CR17","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1056\/NEJMoa2309728","volume":"392","author":"SJ Harrison","year":"2025","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma after cilta-cel therapy for relapsed or refractory myeloma. N. Engl. J. Med. 392, 677\u2013685 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR18","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood 138, 1391\u20131405 (2021).","journal-title":"Blood"},{"key":"1147_CR19","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa2402730","volume":"391","author":"G Kobbe","year":"2024","unstructured":"Kobbe, G. et al. Aggressive lymphoma after CD19 CAR T-cell therapy. N. Engl. J. Med. 391, 1217\u20131226 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR20","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton, M. P. et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 390, 2047\u20132060 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"1147_CR22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1056\/NEJMc2408733","volume":"391","author":"J Godfrey","year":"2024","unstructured":"Godfrey, J., Querfeld, C. & Song, J. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N. Engl. J. Med. 391, 869\u2013870 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR23","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/blood-2023-182817","volume":"142","author":"P Li","year":"2023","unstructured":"Li, P. et al. C-CAR039, a novel anti-CD20\/CD19 bi-specific CAR T-cell therapy shows deep and durable clinical benefits in patients with relapsed or refractory (r\/r) B-cell non-Hodgkin lymphoma (B-NHL) in long term follow up. Blood 142, 1025\u20131025 (2023).","journal-title":"Blood"},{"key":"1147_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(25)02435-3","volume":"407","author":"ML Palomba","year":"2026","unstructured":"Palomba, M. L. et al. Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study. Lancet 407, 963\u2013975 (2026).","journal-title":"Lancet"},{"key":"1147_CR25","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36, 1720\u20131748 (2022).","journal-title":"Leukemia"},{"key":"1147_CR26","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo, E. et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood 140, 1229\u20131253 (2022).","journal-title":"Blood"},{"key":"1147_CR27","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2023021786","volume":"144","author":"L De Leval","year":"2024","unstructured":"De Leval, L., Gaulard, P. & Dogan, A. A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas. Blood 144, 1855\u20131872 (2024).","journal-title":"Blood"},{"key":"1147_CR28","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.3324\/haematol.2023.282719","volume":"108","author":"KJ Savage","year":"2023","unstructured":"Savage, K. J. & De Leval, L. Introduction to the peripheral T-cell lymphoma review series: advances in molecular characterization, classification refinement and treatment optimization. Haematologica 108, 3204\u20133210 (2023).","journal-title":"Haematologica"},{"key":"1147_CR29","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","volume":"31","author":"R Dulery","year":"2025","unstructured":"Dulery, R. et al. T cell malignancies after CAR T\u2009cell therapy in the DESCAR-T registry. Nat. Med. 31, 1130\u20131133 (2025).","journal-title":"Nat. Med."},{"key":"1147_CR30","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab, M. et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood 143, 2099\u20132105 (2024).","journal-title":"Blood"},{"key":"1147_CR31","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","volume":"31","author":"JK Jadlowsky","year":"2025","unstructured":"Jadlowsky, J. K. et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat. Med. 31, 1134\u20131144 (2025).","journal-title":"Nat. Med."},{"key":"1147_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood.2022015728","volume":"140","author":"DHM Steffin","year":"2022","unstructured":"Steffin, D. H. M. et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood 140, 16\u201324 (2022).","journal-title":"Blood"},{"key":"1147_CR33","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.20.01467","volume":"38","author":"KM Cappell","year":"2020","unstructured":"Cappell, K. M. et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 38, 3805\u20133815 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1147_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-025-01676-4","volume":"18","author":"E Umyarova","year":"2025","unstructured":"Umyarova, E. et al. Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies. J. Hematol. Oncol. 18, 30 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"1147_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.61683","volume":"8","author":"L Camacho-Arteaga","year":"2025","unstructured":"Camacho-Arteaga, L. et al. Late adverse events after chimeric antigen receptor T-cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma. JAMA Netw. Open 8, e2461683 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1147_CR36","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1182\/bloodadvances.2022008093","volume":"6","author":"EM Hsieh","year":"2022","unstructured":"Hsieh, E. M. et al. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Adv. 6, 5222\u20135226 (2022).","journal-title":"Blood Adv."},{"key":"1147_CR37","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat. Med. 30, 338\u2013341 (2024).","journal-title":"Nat. Med."},{"key":"1147_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101272","volume":"71","author":"S Pagliuca","year":"2025","unstructured":"Pagliuca, S. et al. The landscape of immune monitoring in CAR-T cell therapy: a comprehensive review and survey study by the cellular therapy and immunobiology working party of the EBMT. Blood Rev. 71, 101272 (2025).","journal-title":"Blood Rev."},{"key":"1147_CR39","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1007\/s00277-023-05454-5","volume":"102","author":"M Andersen Jr.","year":"2023","unstructured":"Andersen, M. Jr. et al. Clonal myeloid disorders following CAR T-cell therapy. Ann. Hematol. 102, 3643\u20133645 (2023).","journal-title":"Ann. Hematol."},{"key":"1147_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1063986","volume":"13","author":"A Zhao","year":"2022","unstructured":"Zhao, A. et al. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory\/relapsed B-cell lymphoma: case series and review of literature. Front. Immunol. 13, 1063986 (2022).","journal-title":"Front. Immunol."},{"key":"1147_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102684","volume":"73","author":"J Shen","year":"2024","unstructured":"Shen, J. et al. Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. EClinicalMedicine 73, 102684 (2024).","journal-title":"EClinicalMedicine"},{"key":"1147_CR42","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41375-025-02605-7","volume":"39","author":"N Gazeau","year":"2025","unstructured":"Gazeau, N. et al. Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time? Leukemia 39, 1714\u20131722 (2025).","journal-title":"Leukemia"},{"key":"1147_CR43","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1182\/bloodadvances.2024012573","volume":"8","author":"M Melody","year":"2024","unstructured":"Melody, M. et al. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood Adv. 8, 2327\u20132331 (2024).","journal-title":"Blood Adv."},{"key":"1147_CR44","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix, T. et al. Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clin. Cancer Res. 30, 4690\u20134700 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1147_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00707-4","volume":"12","author":"HB Alkhateeb","year":"2022","unstructured":"Alkhateeb, H. B. et al. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Cancer J. 12, 113 (2022).","journal-title":"Blood Cancer J."},{"key":"1147_CR46","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1001\/jamaoncol.2023.7182","volume":"10","author":"M Gurney","year":"2024","unstructured":"Gurney, M. et al. Features and factors associated with myeloid neoplasms after chimeric antigen receptor T-cell therapy. JAMA Oncol. 10, 532\u2013535 (2024).","journal-title":"JAMA Oncol."},{"key":"1147_CR47","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41409-025-02529-x","volume":"60","author":"M Farina","year":"2025","unstructured":"Farina, M. et al. Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study. Bone Marrow Transplant. 60, 702\u2013704 (2025).","journal-title":"Bone Marrow Transplant."},{"key":"1147_CR48","doi-asserted-by":"publisher","unstructured":"Hamilton, M. P. et al. CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. Preprint at Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-7746241\/v1 (2025).","DOI":"10.21203\/rs.3.rs-7746241\/v1"},{"key":"1147_CR49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJM200301163480314","volume":"348","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina, S. et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255\u2013256 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR50","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415\u2013419 (2003).","journal-title":"Science"},{"key":"1147_CR51","doi-asserted-by":"publisher","first-page":"227ra233","DOI":"10.1126\/scitranslmed.3007280","volume":"6","author":"CJ Braun","year":"2014","unstructured":"Braun, C. J. et al. Gene therapy for Wiskott\u2013Aldrich syndrome-long-term efficacy and genotoxicity. Sci. Transl. Med. 6, 227ra233 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1147_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28762-2","volume":"13","author":"F Tucci","year":"2022","unstructured":"Tucci, F., Galimberti, S., Naldini, L., Valsecchi, M. G. & Aiuti, A. A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders. Nat. Commun. 13, 1315 (2022).","journal-title":"Nat. Commun."},{"key":"1147_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47866-5","volume":"15","author":"D Cesana","year":"2024","unstructured":"Cesana, D. et al. A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID. Nat. Commun. 15, 3662 (2024).","journal-title":"Nat. Commun."},{"key":"1147_CR54","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2109167","volume":"386","author":"S Goyal","year":"2022","unstructured":"Goyal, S. et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N. Engl. J. Med. 386, 138\u2013147 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR55","doi-asserted-by":"crossref","unstructured":"Assessing the risks of engineered T cells. Nat. Med. 31, 1079\u20131080 (2025).","DOI":"10.1038\/s41591-025-03598-7"},{"key":"1147_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13880-1","volume":"11","author":"A Sheih","year":"2020","unstructured":"Sheih, A. et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat. Commun. 11, 219 (2020).","journal-title":"Nat. Commun."},{"key":"1147_CR57","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/imcb.12254","volume":"97","author":"AD McLellan","year":"2019","unstructured":"McLellan, A. D. & Ali Hosseini Rad, S. M. Chimeric antigen receptor T cell persistence and memory cell formation. Immunol. Cell Biol. 97, 664\u2013674 (2019).","journal-title":"Immunol. Cell Biol."},{"key":"1147_CR58","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25, 285\u2013295 (2017).","journal-title":"Mol. Ther."},{"key":"1147_CR60","doi-asserted-by":"publisher","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra138 (2013).","journal-title":"Sci. Transl. Med."},{"key":"1147_CR61","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123\u20132138 (2016).","journal-title":"J. Clin. Invest."},{"key":"1147_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","volume":"42","author":"S Kaczanowska","year":"2024","unstructured":"Kaczanowska, S. et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell 42, 35\u201351.e38 (2024).","journal-title":"Cancer Cell"},{"key":"1147_CR63","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","volume":"2","author":"L Biasco","year":"2021","unstructured":"Biasco, L. et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat. Cancer 2, 629\u2013642 (2021).","journal-title":"Nat. Cancer"},{"key":"1147_CR64","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 602, 503\u2013509 (2022).","journal-title":"Nature"},{"key":"1147_CR65","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","volume":"8","author":"G Ledergor","year":"2024","unstructured":"Ledergor, G. et al. CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 8, 3562\u20133575 (2024).","journal-title":"Blood Adv."},{"key":"1147_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59298-w","volume":"16","author":"G Cao","year":"2025","unstructured":"Cao, G. et al. Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat. Commun. 16, 4205 (2025).","journal-title":"Nat. Commun."},{"key":"1147_CR67","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41591-025-04121-8","volume":"32","author":"M Ho","year":"2026","unstructured":"Ho, M. et al. CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy. Nat. Med. 32, 702\u2013716 (2026).","journal-title":"Nat. Med."},{"key":"1147_CR68","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1182\/blood-2023-178743","volume":"142","author":"NWCJ Van De Donk","year":"2023","unstructured":"Van De Donk, N. W. C. J. et al. Clinical experience with cranial nerve impairment in the CARTITUDE-1, CARTITUDE-2 cohorts A, B, and C, and cartitude-4 studies of ciltacabtagene autoleucel (cilta-cel). Blood 142, 3501\u20133501 (2023).","journal-title":"Blood"},{"key":"1147_CR69","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1182\/blood-2024-201783","volume":"144","author":"AD Kumar","year":"2024","unstructured":"Kumar, A. D. et al. Delayed neurotoxicity after CAR-T in multiple myeloma: results from a global IMWG registry. Blood 144, 4758\u20134758 (2024).","journal-title":"Blood"},{"key":"1147_CR70","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1182\/blood.2023021787","volume":"144","author":"J Iqbal","year":"2024","unstructured":"Iqbal, J., Inghirami, G. & Chan, W. C. New insights into the biology of T-cell lymphomas. Blood 144, 1873\u20131886 (2024).","journal-title":"Blood"},{"key":"1147_CR71","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.3324\/haematol.2023.282716","volume":"108","author":"B Bisig","year":"2023","unstructured":"Bisig, B., Savage, K. J. & De Leval, L. Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions. Haematologica 108, 3227\u20133243 (2023).","journal-title":"Haematologica"},{"key":"1147_CR72","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","volume":"35","author":"C Laurent","year":"2017","unstructured":"Laurent, C. et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the french lymphopath network. J. Clin. Oncol. 35, 2008\u20132017 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1147_CR73","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S1470-2045(09)70351-1","volume":"11","author":"JK Chan","year":"2010","unstructured":"Chan, J. K. & Kwong, Y. L. Common misdiagnoses in lymphomas and avoidance strategies. Lancet Oncol. 11, 579\u2013588 (2010).","journal-title":"Lancet Oncol."},{"key":"1147_CR74","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/ajcp\/aqw213","volume":"147","author":"D Gratzinger","year":"2017","unstructured":"Gratzinger, D. et al. T- and NK-cell lymphomas and systemic lymphoproliferative disorders and the immunodeficiency setting: 2015 SH\/EAHP workshop report \u2014 part 4. Am. J. Clin. Pathol. 147, 188\u2013203 (2017).","journal-title":"Am. J. Clin. Pathol."},{"key":"1147_CR75","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","volume":"21","author":"JS Brown","year":"2023","unstructured":"Brown, J. S. et al. Updating the definition of cancer. Mol. Cancer Res. 21, 1142\u20131147 (2023).","journal-title":"Mol. Cancer Res."},{"key":"1147_CR76","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2013-07-512830","volume":"122","author":"AM Perry","year":"2013","unstructured":"Perry, A. M. et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood 122, 3599\u20133606 (2013).","journal-title":"Blood"},{"key":"1147_CR77","unstructured":"US Food & Drug Administration. FDA approves labeling changes that include a boxed warning for immune effector cell-associated enterocolitis following treatment with ciltacabtagene autoleucel (Carvykti, Janssen Biotech, Inc.). Medical product safety information. FDA https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/fda-approves-labeling-changes-include-boxed-warning-immune-effector-cell-associated-enterocolitis (2025)."},{"key":"1147_CR78","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.2020010497","volume":"138","author":"D Chihara","year":"2021","unstructured":"Chihara, D., Dores, G. M., Flowers, C. R. & Morton, L. M. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 138, 785\u2013789 (2021).","journal-title":"Blood"},{"key":"1147_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62709-7","volume":"16","author":"K Maurer","year":"2025","unstructured":"Maurer, K. et al. A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy. Nat. Commun. 16, 7462 (2025).","journal-title":"Nat. Commun."},{"key":"1147_CR80","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","volume":"48","author":"BV Kumar","year":"2018","unstructured":"Kumar, B. V., Connors, T. J. & Farber, D. L. Human T cell development, localization, and function throughout life. Immunity 48, 202\u2013213 (2018).","journal-title":"Immunity"},{"key":"1147_CR81","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145\u2013161 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1147_CR82","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/s41591-021-01521-4","volume":"27","author":"A Niroula","year":"2021","unstructured":"Niroula, A. et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat. Med. 27, 1921\u20131927 (2021).","journal-title":"Nat. Med."},{"key":"1147_CR83","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4492","volume":"386","author":"TG Kang","year":"2024","unstructured":"Kang, T. G. et al. Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy. Science 386, eadl4492 (2024).","journal-title":"Science"},{"key":"1147_CR84","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6985031","volume":"2018","author":"H Ma","year":"2018","unstructured":"Ma, H., Gao, W., Sun, X. & Wang, W. STAT5 and TET2 cooperate to regulate FOXP3\u2013TSDR demethylation in CD4+ T cells of patients with colorectal cancer. J. Immunol. Res. 2018, 6985031 (2018).","journal-title":"J. Immunol. Res."},{"key":"1147_CR85","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4049\/jimmunol.1700559","volume":"200","author":"SA Carty","year":"2018","unstructured":"Carty, S. A. et al. The loss of TET2 promotes CD8+ T cell memory differentiation. J. Immunol. 200, 82\u201391 (2018).","journal-title":"J. Immunol."},{"key":"1147_CR86","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1158\/0008-5472.CAN-20-3213","volume":"81","author":"M Lee","year":"2021","unstructured":"Lee, M. et al. Tet2 inactivation enhances the antitumor activity of tumor-infiltrating lymphocytes. Cancer Res. 81, 1965\u20131976 (2021).","journal-title":"Cancer Res."},{"key":"1147_CR87","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp9371","volume":"10","author":"AJ Dimitri","year":"2024","unstructured":"Dimitri, A. J. et al. TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function. Sci. Adv. 10, eadp9371 (2024).","journal-title":"Sci. Adv."},{"key":"1147_CR88","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing, B. et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci. Transl. Med. 13, eabh0272 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1147_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109796","volume":"37","author":"CC Zebley","year":"2021","unstructured":"Zebley, C. C. et al. Proinflammatory cytokines promote TET2-mediated DNA demethylation during CD8 T cell effector differentiation. Cell Rep. 37, 109796 (2021).","journal-title":"Cell Rep."},{"key":"1147_CR90","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood.2019003079","volume":"135","author":"S Boettcher","year":"2020","unstructured":"Boettcher, S. et al. Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood 135, 1548\u20131559 (2020).","journal-title":"Blood"},{"key":"1147_CR91","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.21.02286","volume":"40","author":"CJ Gibson","year":"2022","unstructured":"Gibson, C. J. et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J. Clin. Oncol. 40, 189\u2013201 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1147_CR92","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2017.104","volume":"31","author":"S Herold","year":"2017","unstructured":"Herold, S. et al. Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient. Leukemia 31, 1637\u20131640 (2017).","journal-title":"Leukemia"},{"key":"1147_CR93","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/leu.2016.63","volume":"30","author":"LP Gondek","year":"2016","unstructured":"Gondek, L. P. et al. Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia 30, 1916\u20131920 (2016).","journal-title":"Leukemia"},{"key":"1147_CR94","doi-asserted-by":"publisher","first-page":"eaax6249","DOI":"10.1126\/scitranslmed.aax6249","volume":"12","author":"WH Wong","year":"2020","unstructured":"Wong, W. H. et al. Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. Sci. Transl. Med. 12, eaax6249 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1147_CR95","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","volume":"5","author":"PG Miller","year":"2021","unstructured":"Miller, P. G. et al. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 5, 2982\u20132986 (2021).","journal-title":"Blood Adv."},{"key":"1147_CR96","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000957","volume":"7","author":"V Panagiota","year":"2023","unstructured":"Panagiota, V. et al. Clinical implications and dynamics of clonal hematopoiesis in anti-CD19 CAR T-cell treated patients. Hemasphere 7, e957 (2023).","journal-title":"Hemasphere"},{"key":"1147_CR97","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/bloodadvances.2021005747","volume":"6","author":"R Teipel","year":"2022","unstructured":"Teipel, R. et al. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 6, 1941\u20131946 (2022).","journal-title":"Blood Adv."},{"key":"1147_CR98","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/s43018-025-01009-x","volume":"6","author":"F Yi","year":"2025","unstructured":"Yi, F. et al. CAR-engineered lymphocyte persistence is governed by a FAS ligand\u2013FAS autoregulatory circuit. Nat. Cancer 6, 1638\u20131655 (2025).","journal-title":"Nat. Cancer"},{"key":"1147_CR99","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"1147_CR100","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/978-1-0716-0146-4_17","volume":"2086","author":"H Calderon","year":"2020","unstructured":"Calderon, H., Mamonkin, M. & Guedan, S. Analysis of CAR-mediated tonic signaling. Methods Mol. Biol. 2086, 223\u2013236 (2020).","journal-title":"Methods Mol. Biol."},{"key":"1147_CR101","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/2326-6066.CIR-20-0451","volume":"9","author":"E Landoni","year":"2021","unstructured":"Landoni, E. et al. Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling. Cancer Immunol. Res. 9, 441\u2013453 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"1147_CR102","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.celrep.2017.09.015","volume":"21","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva, D. et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival and is vector-dependent. Cell Rep. 21, 17\u201326 (2017).","journal-title":"Cell Rep."},{"key":"1147_CR103","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025032347","author":"V Blumenberg","year":"2026","unstructured":"Blumenberg, V. et al. Ruxolitinib for ciltacabtagene autoleucel-associated refractory diarrhea. Blood https:\/\/doi.org\/10.1182\/blood.2025032347 (2026).","journal-title":"Blood"},{"key":"1147_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44648-3","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang, S. et al. Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma. Nat. Commun. 15, 360 (2024).","journal-title":"Nat. Commun."},{"key":"1147_CR105","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1158\/2643-3230.BCD-24-0163","volume":"6","author":"D Luan","year":"2025","unstructured":"Luan, D. et al. Dynamics of immune reconstitution and impact on outcomes across CAR-T cell products in large B-cell lymphoma. Blood Cancer Discov. 6, 119\u2013130 (2025).","journal-title":"Blood Cancer Discov."},{"key":"1147_CR106","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1182\/bloodadvances.2024015346","volume":"9","author":"A Riedel","year":"2025","unstructured":"Riedel, A. et al. Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution. Blood Adv. 9, 3149\u20133158 (2025).","journal-title":"Blood Adv."},{"key":"1147_CR107","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.bbmt.2012.07.007","volume":"18","author":"S Nann-R\u00fctti","year":"2012","unstructured":"Nann-R\u00fctti, S. et al. Large granular lymphocyte expansion after allogeneic hematopoietic stem cell transplant is associated with a cytomegalovirus reactivation and shows an indolent outcome. Biol. Blood Marrow Transplant. 18, 1765\u20131770 (2012).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"1147_CR108","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1182\/blood.V87.8.3523.bloodjournal8783523","volume":"87","author":"D Ergas","year":"1996","unstructured":"Ergas, D., Resnitzky, P. & Berrebi, A. Pure red blood cell aplasia associated with parvovirus B19 infection in large granular lymphocyte leukemia. Blood 87, 3523\u20133524 (1996).","journal-title":"Blood"},{"key":"1147_CR109","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3904","volume":"15","author":"B Silva-Santos","year":"2015","unstructured":"Silva-Santos, B., Serre, K. & Norell, H. \u03b3\u03b4 T cells in cancer. Nat. Rev. Immunol. 15, 683\u2013691 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1147_CR110","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","volume":"99","author":"O Yoshie","year":"2002","unstructured":"Yoshie, O. et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99, 1505\u20131511 (2002).","journal-title":"Blood"},{"key":"1147_CR111","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","volume":"116","author":"JJ Campbell","year":"2010","unstructured":"Campbell, J. J., Clark, R. A., Watanabe, R. & Kupper, T. S. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116, 767\u2013771 (2010).","journal-title":"Blood"},{"key":"1147_CR112","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1182\/blood.V96.2.685.014k26_685_690","volume":"96","author":"D Jones","year":"2000","unstructured":"Jones, D. et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 96, 685\u2013690 (2000).","journal-title":"Blood"},{"key":"1147_CR113","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"1147_CR114","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41586-024-07762-w","volume":"634","author":"Z Bai","year":"2024","unstructured":"Bai, Z. et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 634, 702\u2013711 (2024).","journal-title":"Nature"},{"key":"1147_CR115","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1003548","volume":"363","author":"K Boztug","year":"2010","unstructured":"Boztug, K. et al. Stem-cell gene therapy for the Wiskott\u2013Aldrich syndrome. N. Engl. J. Med. 363, 1918\u20131927 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR116","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1182\/blood-2005-08-024976","volume":"108","author":"U Modlich","year":"2006","unstructured":"Modlich, U. et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108, 2545\u20132553 (2006).","journal-title":"Blood"},{"key":"1147_CR117","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/s41587-023-01974-7","volume":"42","author":"JA Greig","year":"2024","unstructured":"Greig, J. A. et al. Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration. Nat. Biotechnol. 42, 1232\u20131242 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1147_CR118","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood-2007-12-128751","volume":"112","author":"S Newrzela","year":"2008","unstructured":"Newrzela, S. et al. Resistance of mature T cells to oncogene transformation. Blood 112, 2278\u20132286 (2008).","journal-title":"Blood"},{"key":"1147_CR119","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1182\/blood.2024025828","volume":"144","author":"J Hu","year":"2024","unstructured":"Hu, J. & Dunbar, C. E. T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities. Blood 144, 2473\u20132481 (2024).","journal-title":"Blood"},{"key":"1147_CR120","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/nmeth1103","volume":"4","author":"M Schmidt","year":"2007","unstructured":"Schmidt, M. et al. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat. Methods 4, 1051\u20131057 (2007).","journal-title":"Nat. Methods"},{"key":"1147_CR121","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1182\/blood-2010-05-283523","volume":"116","author":"C Cattoglio","year":"2010","unstructured":"Cattoglio, C. et al. High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood 116, 5507\u20135517 (2010).","journal-title":"Blood"},{"key":"1147_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03729-5","volume":"20","author":"L Shao","year":"2022","unstructured":"Shao, L. et al. Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products. J. Transl. Med. 20, 514 (2022).","journal-title":"J. Transl. Med."},{"key":"1147_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200833","volume":"32","author":"P G\u0142owacki","year":"2024","unstructured":"G\u0142owacki, P., Tr\u0119da, C. & Rieske, P. Regulation of CAR transgene expression to design semiautonomous CAR-T. Mol. Ther. Oncol. 32, 200833 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"1147_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101352","volume":"32","author":"M Sheehan","year":"2024","unstructured":"Sheehan, M. et al. Comparison and cross-validation of long-read and short-read target-enrichment sequencing methods to assess AAV vector integration into host genome. Mol. Ther. Methods Clin. Dev. 32, 101352 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1147_CR125","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood.2023021789","volume":"144","author":"AJ Moskowitz","year":"2024","unstructured":"Moskowitz, A. J., Stuver, R. N. & Horwitz, S. M. Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs). Blood 144, 1887\u20131897 (2024).","journal-title":"Blood"},{"key":"1147_CR126","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1182\/blood.2023021788","volume":"144","author":"E Marchi","year":"2024","unstructured":"Marchi, E., Craig, J. W. & Kalac, M. Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL, MEITL, SPTCL, and HSTCL). Blood 144, 1898\u20131909 (2024).","journal-title":"Blood"},{"key":"1147_CR127","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.3324\/haematol.2021.280275","volume":"108","author":"HS Ngu","year":"2023","unstructured":"Ngu, H. S. & Savage, K. J. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas. Haematologica 108, 3211\u20133226 (2023).","journal-title":"Haematologica"},{"key":"1147_CR128","unstructured":"US Food & Drug Administration. Workshop on integration site analysis during long-term follow-up for gene therapies with integrating viral vectors. FDA https:\/\/www.fda.gov\/news-events\/otp-events-meetings-and-workshops\/workshop-integration-site-analysis-during-long-term-follow-gene-therapies-integrating-viral-vectors (2024)."},{"key":"1147_CR129","unstructured":"US Food & Drug Administration. Long term follow-up after administration of human gene therapy products. Guidance for industry. FDA https:\/\/www.fda.gov\/media\/113768\/download (2026)."},{"key":"1147_CR130","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41409-024-02446-5","volume":"60","author":"RD Guerrettaz","year":"2025","unstructured":"Guerrettaz, R. D., Spellman, S. R. & Page, K. M. Role of the CIBMTR biorepository and registry in precision transplantation research. Bone Marrow Transplant. 60, 161\u2013164 (2025).","journal-title":"Bone Marrow Transplant."},{"key":"1147_CR131","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna, G. G. et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 14, 180 (2024).","journal-title":"Blood Cancer J."},{"key":"1147_CR132","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1149450","volume":"13","author":"S Zundler","year":"2023","unstructured":"Zundler, S. et al. Case report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma. Front. Oncol. 13, 1149450 (2023).","journal-title":"Front. Oncol."},{"key":"1147_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01320-x","volume":"15","author":"R Banerjee","year":"2025","unstructured":"Banerjee, R. et al. Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma. Blood Cancer J. 15, 112 (2025).","journal-title":"Blood Cancer J."},{"key":"1147_CR134","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S2152-2650(24)01911-6","volume":"24","author":"N Bar","year":"2024","unstructured":"Bar, N. et al. P-008 a rare and unexplored entity of colitis post-BCMA directed CAR T-cell therapy; insights from a multicenter case series. Clin. Lymphoma Myeloma Leuk. 24, S44\u2013S45 (2024).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1147_CR135","doi-asserted-by":"publisher","first-page":"S315","DOI":"10.14309\/01.ajg.0001133312.83127.79","volume":"120","author":"K Lim","year":"2025","unstructured":"Lim, K., Lin, Y. & Chowla, N. Diagnosis and management of immune effector cell (CAR-T)-associated enterocolitis in multiple myeloma patients. Am. J. Gastroenterol. 120, S315\u2013S315 (2025).","journal-title":"Am. J. Gastroenterol."},{"key":"1147_CR136","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1182\/blood-2025-6366","volume":"146","author":"M Belwadi","year":"2025","unstructured":"Belwadi, M. et al. Immune effector cell-associated enterocolitis (IEC-EC) across CAR-T products in myeloma and lymphoma: a real world pharmacovigilance analysis. Blood 146 (Suppl. 1), 6366 (2025).","journal-title":"Blood"},{"key":"1147_CR137","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/mt.2009.7","volume":"17","author":"CL Li","year":"2009","unstructured":"Li, C. L., Xiong, D., Stamatoyannopoulos, G. & Emery, D. W. Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol. Ther. 17, 716\u2013724 (2009).","journal-title":"Mol. Ther."},{"key":"1147_CR138","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1634\/stemcells.2008-0258","volume":"26","author":"A Ramezani","year":"2008","unstructured":"Ramezani, A., Hawley, T. S. & Hawley, R. G. Combinatorial incorporation of enhancer-blocking components of the chicken \u03b2-globin 5\u2032HS4 and human T-cell receptor \u03b1\/\u03b4BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells 26, 3257\u20133266 (2008).","journal-title":"Stem Cells"},{"key":"1147_CR139","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/sj.gt.3302979","volume":"14","author":"T Higashimoto","year":"2007","unstructured":"Higashimoto, T. et al. The woodchuck hepatitis virus post-transcriptional regulatory element reduces readthrough transcription from retroviral vectors. Gene Ther. 14, 1298\u20131304 (2007).","journal-title":"Gene Ther."},{"key":"1147_CR140","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang, D., Tai, P. W. L. & Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 18, 358\u2013378 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1147_CR141","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku082","volume":"42","author":"SC Verghese","year":"2014","unstructured":"Verghese, S. C., Goloviznina, N. A., Skinner, A. M., Lipps, H. J. & Kurre, P. S\/MAR sequence confers long-term mitotic stability on non-integrating lentiviral vector episomes without selection. Nucleic Acids Res. 42, e53 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1147_CR142","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/s41587-019-0291-z","volume":"37","author":"I Querques","year":"2019","unstructured":"Querques, I. et al. A highly soluble sleeping beauty transposase improves control of gene insertion. Nat. Biotechnol. 37, 1502\u20131512 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1147_CR143","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\u2013Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"1147_CR144","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"1147_CR145","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1147_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19486-2","volume":"11","author":"NN Parayath","year":"2020","unstructured":"Parayath, N. N., Stephan, S. B., Koehne, A. L., Nelson, P. S. & Stephan, M. T. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo. Nat. Commun. 11, 6080 (2020).","journal-title":"Nat. Commun."},{"key":"1147_CR147","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas, C. A. et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med. 24, 1216\u20131224 (2018).","journal-title":"Nat. Med."},{"key":"1147_CR148","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1182\/blood.2023020075","volume":"142","author":"JE Amengual","year":"2023","unstructured":"Amengual, J. E. & Pro, B. How I treat posttransplant lymphoproliferative disorder. Blood 142, 1426\u20131437 (2023).","journal-title":"Blood"},{"key":"1147_CR149","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1182\/hematology.2024000583","volume":"2024","author":"NK El-Mallawany","year":"2024","unstructured":"El-Mallawany, N. K. & Rouce, R. H. EBV and post-transplant lymphoproliferative disorder: a complex relationship. Hematol. Am. Soc. Hematol. Educ. Program 2024, 728\u2013735 (2024).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"1147_CR150","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/ajt.13558","volume":"16","author":"JF Ferreiro","year":"2016","unstructured":"Ferreiro, J. F. et al. EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features. Am. J. Transplant. 16, 414\u2013425 (2016).","journal-title":"Am. J. Transplant."},{"key":"1147_CR151","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068343","volume":"8","author":"E Margolskee","year":"2013","unstructured":"Margolskee, E. et al. Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features. PLoS ONE 8, e68343 (2013).","journal-title":"PLoS ONE"},{"key":"1147_CR152","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/1066896918785985","volume":"27","author":"AM Perry","year":"2019","unstructured":"Perry, A. M., Bailey, N. G., Bonnett, M., Jaffe, E. S. & Chan, W. C. Disease progression in a patient with indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Int. J. Surg. Pathol. 27, 102\u2013107 (2019).","journal-title":"Int. J. Surg. Pathol."},{"key":"1147_CR153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1530149","volume":"16","author":"D Yuan","year":"2025","unstructured":"Yuan, D., Liang, N., Wang, D. Y., Wang, J. J. & Jia, C. W. Clinical and pathological analysis of indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Front. Immunol. 16, 1530149 (2025).","journal-title":"Front. Immunol."},{"key":"1147_CR154","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00428-022-03467-5","volume":"482","author":"W Fan","year":"2023","unstructured":"Fan, W. et al. Indolent T-cell lymphoproliferative disorder of gastrointestinal tract with unusual clinical courses: report of 6 cases and literature review. Virchows Arch. 482, 729\u2013743 (2023).","journal-title":"Virchows Arch."},{"key":"1147_CR155","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1182\/blood-2018-01-830968","volume":"131","author":"A Sharma","year":"2018","unstructured":"Sharma, A. et al. Recurrent STAT3\u2013JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131, 2262\u20132266 (2018).","journal-title":"Blood"},{"key":"1147_CR156","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.3324\/haematol.2019.230961","volume":"105","author":"CR Soderquist","year":"2020","unstructured":"Soderquist, C. R. et al. Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. Haematologica 105, 1895\u20131906 (2020).","journal-title":"Haematologica"},{"key":"1147_CR157","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1001\/jamasurg.2017.4026","volume":"152","author":"AN Leberfinger","year":"2017","unstructured":"Leberfinger, A. N. et al. Breast implant-associated anaplastic large cell lymphoma: a systematic review. JAMA Surg. 152, 1161\u20131168 (2017).","journal-title":"JAMA Surg."},{"key":"1147_CR158","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-12-0101","volume":"18","author":"MG Lechner","year":"2012","unstructured":"Lechner, M. G. et al. Survival signals and targets for therapy in breast implant-associated ALK-anaplastic large cell lymphoma. Clin. Cancer Res. 18, 4549\u20134559 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1147_CR159","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1182\/blood-2017-12-821868","volume":"132","author":"N Oishi","year":"2018","unstructured":"Oishi, N. et al. Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132, 544\u2013547 (2018).","journal-title":"Blood"},{"key":"1147_CR160","doi-asserted-by":"publisher","first-page":"36126","DOI":"10.18632\/oncotarget.26308","volume":"9","author":"P Blombery","year":"2018","unstructured":"Blombery, P. et al. Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. Oncotarget 9, 36126\u201336136 (2018).","journal-title":"Oncotarget"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01147-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01147-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01147-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:02:33Z","timestamp":1782302553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01147-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":160,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1147"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01147-w","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"26 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.A. has served as an advisory board member and\/or consultant for Kite Pharma. M.P.H. has received research funding from Kite\/Gilead. M.D.J. declares consultancy\/advisory roles for and\/or honoraria from Johnson & Johnson, Kite\/Gilead and Prime Education; and has received research funding from Incyte, Kite\/Gilead and Lilly. M.O. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}